Thus, testing secondary mutations may inform treatment options for ovarian cancer patients.87 For example, 6‐thioguanine has been demonstrated to kill cells and tumours that have gained resistance to PARP inhibitors via the genetic reversion of the BRCA2 gene.32, 91. Here, PARP1 is linked to ovarian carcinoma.